Inflammatory Bowel Disease and Risk of Colorectal Cancer: An Overview From Pathophysiology to Pharmacological Prevention

Increased risk of colorectal cancer (CRC) in inflammatory bowel disease (IBD) patients has been attributed to long-standing chronic inflammation, with the contribution of genetic alterations and environmental factors such as the microbiota. Moreover, accumulating data indicate that IBD-associated CR...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucafò, Marianna, Curci, Debora, Franzin, Martina, Decorti, Giuliana, Stocco, Gabriele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563785/
https://www.ncbi.nlm.nih.gov/pubmed/34744751
http://dx.doi.org/10.3389/fphar.2021.772101
_version_ 1784593479098171392
author Lucafò, Marianna
Curci, Debora
Franzin, Martina
Decorti, Giuliana
Stocco, Gabriele
author_facet Lucafò, Marianna
Curci, Debora
Franzin, Martina
Decorti, Giuliana
Stocco, Gabriele
author_sort Lucafò, Marianna
collection PubMed
description Increased risk of colorectal cancer (CRC) in inflammatory bowel disease (IBD) patients has been attributed to long-standing chronic inflammation, with the contribution of genetic alterations and environmental factors such as the microbiota. Moreover, accumulating data indicate that IBD-associated CRC (IBD-CRC) may initiate and develop through a pathway of tumorigenesis distinct from that of sporadic CRC. This mini-review summarizes the current knowledge of IBD-CRC, focusing on the main mechanisms underlying its pathogenesis, and on the important role of immunomodulators and biologics used to treat IBD patients in interfering with the inflammatory process involved in carcinogenesis.
format Online
Article
Text
id pubmed-8563785
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85637852021-11-04 Inflammatory Bowel Disease and Risk of Colorectal Cancer: An Overview From Pathophysiology to Pharmacological Prevention Lucafò, Marianna Curci, Debora Franzin, Martina Decorti, Giuliana Stocco, Gabriele Front Pharmacol Pharmacology Increased risk of colorectal cancer (CRC) in inflammatory bowel disease (IBD) patients has been attributed to long-standing chronic inflammation, with the contribution of genetic alterations and environmental factors such as the microbiota. Moreover, accumulating data indicate that IBD-associated CRC (IBD-CRC) may initiate and develop through a pathway of tumorigenesis distinct from that of sporadic CRC. This mini-review summarizes the current knowledge of IBD-CRC, focusing on the main mechanisms underlying its pathogenesis, and on the important role of immunomodulators and biologics used to treat IBD patients in interfering with the inflammatory process involved in carcinogenesis. Frontiers Media S.A. 2021-10-20 /pmc/articles/PMC8563785/ /pubmed/34744751 http://dx.doi.org/10.3389/fphar.2021.772101 Text en Copyright © 2021 Lucafò, Curci, Franzin, Decorti and Stocco. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Lucafò, Marianna
Curci, Debora
Franzin, Martina
Decorti, Giuliana
Stocco, Gabriele
Inflammatory Bowel Disease and Risk of Colorectal Cancer: An Overview From Pathophysiology to Pharmacological Prevention
title Inflammatory Bowel Disease and Risk of Colorectal Cancer: An Overview From Pathophysiology to Pharmacological Prevention
title_full Inflammatory Bowel Disease and Risk of Colorectal Cancer: An Overview From Pathophysiology to Pharmacological Prevention
title_fullStr Inflammatory Bowel Disease and Risk of Colorectal Cancer: An Overview From Pathophysiology to Pharmacological Prevention
title_full_unstemmed Inflammatory Bowel Disease and Risk of Colorectal Cancer: An Overview From Pathophysiology to Pharmacological Prevention
title_short Inflammatory Bowel Disease and Risk of Colorectal Cancer: An Overview From Pathophysiology to Pharmacological Prevention
title_sort inflammatory bowel disease and risk of colorectal cancer: an overview from pathophysiology to pharmacological prevention
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563785/
https://www.ncbi.nlm.nih.gov/pubmed/34744751
http://dx.doi.org/10.3389/fphar.2021.772101
work_keys_str_mv AT lucafomarianna inflammatoryboweldiseaseandriskofcolorectalcanceranoverviewfrompathophysiologytopharmacologicalprevention
AT curcidebora inflammatoryboweldiseaseandriskofcolorectalcanceranoverviewfrompathophysiologytopharmacologicalprevention
AT franzinmartina inflammatoryboweldiseaseandriskofcolorectalcanceranoverviewfrompathophysiologytopharmacologicalprevention
AT decortigiuliana inflammatoryboweldiseaseandriskofcolorectalcanceranoverviewfrompathophysiologytopharmacologicalprevention
AT stoccogabriele inflammatoryboweldiseaseandriskofcolorectalcanceranoverviewfrompathophysiologytopharmacologicalprevention

Ejemplares similares